Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 6/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681375 | 0.83 | GAA (0.61) | OPRK1BCHEEPHX1LMNAMEN1 | |
| SCHEMBL3681373 | 0.83 | GAA (0.61) | OPRK1BCHEEPHX1LMNAMEN1 | |
| SCHEMBL524374 | 0.81 | APAF1 (0.62) | LMNAMEN1KMT2ANPSR1APAF1 | |
| SCHEMBL653596 | 0.81 | APAF1 (0.62) | LMNAMEN1KMT2ANPSR1APAF1 | |
| SCHEMBL157741 | 0.81 | APAF1 (0.62) | LMNAMEN1KMT2ANPSR1APAF1 | |
| SCHEMBL157039 | 0.76 | EPHX1 (0.50) | EPHX1LMNAMEN1KMT2AL3MBTL1 | |
| Glycine SCHEMBL27727845 | 0.75 | APAF1 (0.56) | LMNAMEN1KMT2ANPSR1GAA | |
| SCHEMBL12410231 | 0.75 | SIGMAR1 (0.61) | LMNAMEN1KMT2ANPSR1GAA | |
| Bicarbonate SCHEMBL11119101 | 0.75 | BCHE (0.54) | OPRK1BCHEEPHX1MEN1KMT2A | |
| SCHEMBL8165369 | 0.74 | CYP2D6 (0.47) | EPHX1LMNAMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | OPRK1 1311/4885BCHE 4291/4885EPHX1 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.